Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial

卡培他滨 医学 奥沙利铂 内科学 氟尿嘧啶 危险系数 放化疗 肿瘤科 化疗 胃肠病学 癌症 结直肠癌 置信区间
作者
Ruinuo Jia,Tanyou Shan,Anping Zheng,Yaowen Zhang,Ping Lu,Guifang Zhang,Wang Feng,Zhiqiao Xu,Guobao Zheng,Dongxia Tang,Weiguo Zhang,Wanying Li,Ruonan Li,Yibo Guo,Lina Liu,Xiaoyong Luo,Yingjuan Zheng,Zhiwei Chang,Qiming Wang,Xinshuai Wang,Xiaozhi Yuan,Guoqiang Kong,Shuoguo Li,Yang Ruina,Dan Zhou,Jing Ren,Weijiao Yin,Jingxia Li,Junqian Zhang,Ziqi Wang,Manxi Sheng,Bingyi Xu,Liuyan Li,Xiaoyi Liu,Zhihao Lu,Lixin Wan,Fuyou Zhou,Shegan Gao
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (20): 2436-2445 被引量:4
标识
DOI:10.1200/jco.23.02009
摘要

PURPOSE This phase 3 trial aimed to compare the efficacy and safety of capecitabine or capecitabine plus oxaliplatin (XELOX) with those of fluorouracil plus cisplatin (PF) in definitive concurrent chemoradiotherapy (DCRT) for inoperable locally advanced esophageal squamous cell carcinoma (ESCC). METHODS Patients were randomly assigned to receive two cycles of capecitabine, XELOX, or PF along with concurrent intensity-modulated radiation therapy. Patients in each arm were again randomly assigned to receive two cycles of consolidation chemotherapy or not. The primary end points were 2-year overall survival (OS) rate and incidence of grade ≥3 adverse events (AEs). RESULTS A total of 246 patients were randomly assigned into the capecitabine (n = 80), XELOX (n = 85), and PF (n = 81) arms. In capecitabine, XELOX, and PF arms, the 2-year OS rate was 75%, 66.7%, and 70.9% (capecitabine v PF: hazard ratio [HR], 0.91 [95% CI, 0.61 to 1.35]; nominal P = .637; XELOX v PF: 0.86 [95% CI, 0.58 to 1.27]; P = .444); the median OS was 40.9 (95% CI, 34.4 to 49.9), 41.9 (95% CI, 28.6 to 52.1), and 35.4 (95% CI, 30.4 to 45.4) months. The incidence of grade ≥3 AEs during the entire treatment was 28.8%, 36.5%, and 45.7%, respectively. Comparing the consolidation chemotherapy with the nonconsolidation chemotherapy groups, the median OS was 41.9 (95% CI, 34.6 to 52.8) versus 36.9 (95% CI, 28.5 to 44) months (HR, 0.71 [95% CI, 0.52 to 0.99]; nominal P = .0403). CONCLUSION Capecitabine or XELOX did not significantly improve the 2-year OS rate over PF in DCRT for inoperable locally advanced ESCC. Capecitabine showed a lower incidence of grade ≥3 AEs than PF did.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
朴素羊完成签到 ,获得积分10
刚刚
刚刚
小马甲应助小王采纳,获得10
刚刚
俭朴羊青完成签到,获得积分10
1秒前
张张完成签到,获得积分10
3秒前
tomorrow完成签到 ,获得积分10
4秒前
糖炒栗子完成签到,获得积分10
5秒前
现代期待完成签到,获得积分10
5秒前
小黎完成签到,获得积分10
6秒前
呼呼呼完成签到,获得积分10
6秒前
无花果应助晴云采纳,获得10
6秒前
寸草的晖完成签到,获得积分10
7秒前
8秒前
8秒前
8秒前
小燕子发布了新的文献求助10
9秒前
10秒前
顺顺完成签到,获得积分10
11秒前
jiachun完成签到,获得积分10
11秒前
jiaolulu发布了新的文献求助10
11秒前
小王发布了新的文献求助10
12秒前
queen814完成签到,获得积分10
12秒前
简单发布了新的文献求助10
13秒前
一只呆果蝇完成签到,获得积分10
13秒前
Eternity完成签到,获得积分10
14秒前
研友_VZG7GZ应助落后从阳采纳,获得10
14秒前
乐观寻绿完成签到,获得积分10
15秒前
Hover完成签到,获得积分0
15秒前
莫晓岚完成签到,获得积分10
15秒前
123完成签到 ,获得积分10
16秒前
所所应助JSY采纳,获得30
16秒前
默默的立辉完成签到,获得积分10
16秒前
Yh完成签到,获得积分10
16秒前
引子完成签到,获得积分10
18秒前
机智的阿振完成签到,获得积分10
19秒前
KatzeBaliey完成签到,获得积分10
20秒前
量子星尘发布了新的文献求助10
21秒前
yar应助大饼采纳,获得10
22秒前
mammer应助一朵云采纳,获得20
22秒前
22秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029